Pavadi Capital’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-41,899
Closed -$6.55M 18
2022
Q4
$6.55M Sell
41,899
-191
-0.5% -$27.4K 6.18% 4
2022
Q3
$5.16M Sell
42,090
-4,066
-9% -$535K 4.94% 5
2022
Q2
$6.14M Buy
46,156
+7,344
+19% +$1M 5.56% 5
2022
Q1
$5.31M Sell
38,812
-3,592
-8% -$501K 4.68% 6
2021
Q4
$7.34M Buy
+42,404
New +$6.45M 5.57% 5

Other funds holding DGX

Pavadi Capital's DGX Position: Q1 2023 in Review

Pavadi Capital sold out of Quest Diagnostics (DGX) in Q1 2023, closing a stake of 41,899 shares — an estimated $6.55M sold.

Pavadi Capital first reported a position in DGX in Q4 2021 and held it in 5 quarters. The position peaked at $7.34M in Q4 2021. 834 funds tracked by Wall St. Rank hold DGX as of Q1 2023.

  • Pavadi Capital reported no remaining Quest Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Pavadi Capital sold 41,899 Quest Diagnostics shares in Q1 2023, an estimated $6.55M.
  • Pavadi Capital first reported a position in Quest Diagnostics in Q4 2021 and held it in 5 quarters.
  • Pavadi Capital's Quest Diagnostics position peaked at $7.34M in Q4 2021.
  • 834 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2023.

Based on Pavadi Capital's 13F filing for Q1 2023, filed 15 May 2023.